June 18, 2025
5 min watch
CHICAGO, June 18, 2025 — New research presented at the ASCO Annual Meeting highlights advances in lymphoma treatment, offering hope for patients.
Experts discussed promising developments in lymphoma therapies, including new drug combinations and the role of circulating tumor DNA.
- New treatment combinations are emerging for aggressive lymphomas.
- Efforts are underway to improve salvage regimens.
- Antibody-drug conjugates and bispecific antibodies show promise.
What are the latest developments in lymphoma treatment? The ASCO Annual Meeting featured discussions on innovative approaches, including the use of circulating tumor DNA and new drugs like antibody-drug conjugates and bispecific antibodies.
“We are continuing to see themes building upon the role of circulating tumor DNA in patients with aggressive lymphomas, we are seeing efforts to build upon specific salvage regimens, such as R-GemOx, and we are seeing new drugs come through like antibody-drug conjugates and bispecific antibodies that are being tested either in new settings or in new combinations or with longer follow-up,” said Sonali M. Smith, MD, Elwood V. Jensen Professor of Medicine and chief of the section of hematology and oncology at University of Chicago Medicine.
